Inari Medical Inc. (NARI): Price and Financial Metrics
NARI Price/Volume Stats
| Current price | $65.40 | 52-week high | $83.84 |
| Prev. close | $66.68 | 52-week low | $52.59 |
| Day low | $65.19 | Volume | 387,700 |
| Day high | $67.25 | Avg. volume | 782,315 |
| 50-day MA | $64.61 | Dividend yield | N/A |
| 200-day MA | $62.28 | Market Cap | 3.75B |
NARI Stock Price Chart Interactive Chart >
NARI POWR Grades
- NARI scores best on the Growth dimension, with a Growth rank ahead of 93.07% of US stocks.
- NARI's strongest trending metric is Growth; it's been moving up over the last 177 days.
- NARI ranks lowest in Momentum; there it ranks in the 6th percentile.
NARI Stock Summary
- With a one year PEG ratio of 3,761.73, INARI MEDICAL INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 99.24% of US stocks.
- Price to trailing twelve month operating cash flow for NARI is currently 614.01, higher than 99.65% of US stocks with positive operating cash flow.
- NARI's price/sales ratio is 8.3; that's higher than the P/S ratio of 88.15% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to INARI MEDICAL INC are FLYW, INSP, PEN, LTRX, and MNTX.
- NARI's SEC filings can be seen here. And to visit INARI MEDICAL INC's official web site, go to www.inarimedical.com.
NARI Valuation Summary
- NARI's price/sales ratio is 8.3; this is 336.84% higher than that of the median Healthcare stock.
- NARI's EV/EBIT ratio has moved up 6916.5 over the prior 41 months.
Below are key valuation metrics over time for NARI.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| NARI | 2023-09-22 | 8.3 | 8.4 | -226.6 | -300.1 |
| NARI | 2023-09-21 | 8.6 | 8.6 | -233.5 | -309.3 |
| NARI | 2023-09-20 | 8.7 | 8.7 | -236.7 | -313.6 |
| NARI | 2023-09-19 | 8.7 | 8.8 | -238.7 | -316.3 |
| NARI | 2023-09-18 | 8.6 | 8.7 | -235.5 | -312.0 |
| NARI | 2023-09-15 | 8.7 | 8.8 | -237.3 | -314.4 |
NARI's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- NARI has a Quality Grade of B, ranking ahead of 85.55% of graded US stocks.
- NARI's asset turnover comes in at 0.917 -- ranking 23rd of 186 Medical Equipment stocks.
- 500 - Internal server error
The table below shows NARI's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.917 | 0.921 | 0.292 |
| 2021-03-31 | 0.774 | 0.912 | 0.271 |
| 2020-12-31 | 0.794 | 0.906 | 0.292 |
NARI Price Target
For more insight on analysts targets of NARI, see our NARI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $119.67 | Average Broker Recommendation | 1.33 (Strong Buy) |
Inari Medical Inc. (NARI) Company Bio
Inari Medical, Inc. operates as a medical device company. It develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in June 2011 and is headquartered in Irvine, CA.
Latest NARI News From Around the Web
Below are the latest news stories about INARI MEDICAL INC that investors may wish to consider to help them evaluate NARI as an investment opportunity.
CFO Mitch Hill Sells 6,500 Shares of Inari Medical IncOn September 12, 2023, Mitch Hill, the Chief Financial Officer of Inari Medical Inc (NASDAQ:NARI), sold 6,500 shares of the company. |
Inari Medical to Present at Upcoming Investor ConferencesIRVINE, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will present at the following investor conferences: 2023 Wells Fargo Healthcare ConferencePresenting on Friday, September 8, 2023 at 8:45 a.m. Eastern Time in Boston, MA at the Encore Boston Harbor 21st Annual Morgan Stanley Global Heal |
Wall Street Analysts See a 36.39% Upside in Inari Medical, Inc. (NARI): Can the Stock Really Move This High?The consensus price target hints at a 36.4% upside potential for Inari Medical, Inc. (NARI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Shockwave Medical (SWAV) Q2 Earnings Miss, Revenues Surge Y/YShockwave Medical's (SWAV) second-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches. |
Is Inari Medical, Inc. (NASDAQ:NARI) Expensive For A Reason? A Look At Its Intrinsic ValueKey Insights Inari Medical's estimated fair value is US$48.94 based on 2 Stage Free Cash Flow to Equity Current share... |
NARI Price Returns
| 1-mo | -1.40% |
| 3-mo | N/A |
| 6-mo | 1.76% |
| 1-year | -9.97% |
| 3-year | 1.52% |
| 5-year | N/A |
| YTD | 2.89% |
| 2022 | -30.36% |
| 2021 | 4.56% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...